Last reviewed · How we verify

ICE — Competitive Intelligence Brief

ICE (ICE) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Caspase inhibitor. Area: Immunology.

marketed Caspase inhibitor Caspase-1 (ICE) Immunology Small molecule Live · refreshed every 30 min

Target snapshot

ICE (ICE) — MedImmune LLC. ICE is an intracellular caspase inhibitor that blocks apoptosis by inhibiting caspase enzymes responsible for programmed cell death.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
ICE TARGET ICE MedImmune LLC marketed Caspase inhibitor Caspase-1 (ICE)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Caspase inhibitor class)

  1. MedImmune LLC · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ICE — Competitive Intelligence Brief. https://druglandscape.com/ci/ice. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: